Autoimmune Army: NIH Patents On-the-Spot Immune Cell Fighters
Published Date: 2/20/2026
Notice
Summary
The National Institutes of Health is fixing a small but important detail in their patent license for a new treatment that uses special immune cells to fight autoimmune diseases. This change clarifies how the treatment’s genetic material is delivered, either by non-viral nanoparticles or viral systems. If you want to comment or apply for a license, you’ve got until March 9, 2026, so don’t miss out!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Viral Delivery (Including Lentivirus) Allowed
If you are a company or researcher seeking an exclusive NIH patent license for an anti-CD19 CAR immunotherapy, the NIH corrected the license language so the therapy can be developed using either a non-viral synthetic nanoparticle delivery system or a viral system — the prior exclusion of lentiviral systems was removed. Written comments or license applications must be received by the NCI Technology Transfer Center on or before March 9, 2026 to be considered.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in